Biofrontera Licenses Xepi Antibiotic Cream to Pelthos for Up to $10M, Bolstering Cash Position.

Biofrontera Inc. has sold its US license for Xepi Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10 million. The transaction bolsters Biofrontera's cash position, expected to fund the company to profitability. Proceeds will support the growth of Biofrontera's commercial PDT platform and expansion of Ameluz into additional indications.